New drug combo shows promise for rare blood disorder

NCT ID NCT05399732

Completed Disease control Sponsor: Bing Han Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested whether adding luspatercept to standard cyclosporine treatment helps people with non-severe aplastic anemia. The study enrolled 58 newly diagnosed adults who had low blood counts but did not yet need transfusions. The goal was to see if the combination could raise hemoglobin levels and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept and cyclosporine
What this could lead to: If it works, this combination could help people with non-severe aplastic anemia improve their red blood cell counts without needing blood transfusions.
What could go wrong: This is a small, phase 2 trial with only 58 participants. The results may not apply to everyone, and side effects from the drugs could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA

Contacts and locations

Locations

Peking union medical college hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.